Investors

Who we are

Alder Therapeutics is a virtual and agile preclinical phase allogeneic stem cell therapy development company that’s shaping the future of regenerative medicine.

Through our unique cell therapy development philosophy — AlderEdge — we overcome the challenges of traditional development approaches, embedding risk reduction, rigorous planning, and commercial-mindedness at the core of cell therapy programs.

Armed with the AlderEdge approach and an industry-renowned team that understands the commercial challenges of bringing cell therapies to market, we’re on a bold mission to cure the incurable.

Our licensed therapies

We have exclusive IP licenses for state-of-the-art methods to manufacture two promising stem cell therapy products

  • Firstly, ALD01, a cell therapy to treat Retinitis Pigmentosa
  • Secondly, ALD02, a cell therapy to treat heart failure

These therapies have the potential to transform the way we treat two diseases with high global burden and significant unmet need.

What’s more, the treatment of each disease represents a multibillion USD commercial opportunity.

Critically, extensive preclinical tests have already demonstrated proof-of-concept for the two programs.

Now, using the AlderEdge approach, we aim to further improve manufacturing of these therapies and propel them through clinical trials.

Our investment journey

To date, we’ve received €3 million in seed funding from the most active and well-respected investment companies in Sweden — Flerie and Linc. We have also successfully raised a substantial sum of non-dilutive funding.

Now, we want to raise €22million to take our lead ALD01 eye cell therapy program through Phase I/IIa clinical trials by 2026, and to take our second ALD02 cardiac program to GLP Tox studies.

Our licensed therapies

We have exclusive IP licenses for state-of-the-art methods to manufacture two promising stem cell therapy products

  • ALD01, a cell therapy to treat Retinitis Pigmentosa
  • ALD02, a cell therapy to treat heart failure

These therapies have the potential to transform the way we treat two diseases with high global burden and significant unmet need.

What’s more, the treatment of each disease represents a multibillion USD commercial opportunity.

Critically, extensive preclinical tests have already demonstrated proof-of-concept for the two programs.

Now, using the AlderEdge™ approach, we aim to further improve manufacturing of these therapies and propel them through clinical trials.

Our investment journey

To date, we’ve received €3 million in seed funding from the most active and well-respected investment companies in Sweden — Flerie and Linc. We have also successfully raised a substantial sum of non-dilutive funding.

Now, we want to raise €25million to take our lead ALD01 eye cell therapy program through Phase I/IIa clinical trials by 2026, and to prepare our second ALD02 cardiac program for GLP Tox studies.

Why work with us

With risk-reduction at our core, a global network of the best industry experts at our fingertips, a seasoned leadership team, and two promising therapies in the pipeline, we offer investors a unique opportunity to achieve optimal returns while transforming the lives of patients.

Kristian Tryggvason, Ph.D., MBA
CEO & Founder

Kristian is responsible for driving preclinical development of the company’s promising pipeline of pluripotent stem cell therapies, in addition to managing PR, marketing, finance and fundraising activities.

Stijn Heessen, Ph.D.
Chief Operations Officer

Stijn is responsible for business development, contracting, regulatory and clinical strategy, and health economics & market access activities for Alder’s cell therapy pipeline.

Professor Dominik Fischer, Ph.D.
Scientific Advisor

Dominik is an Ophthalmic Surgeon at the Oxford Eye Hospital and full Professor of Ophthalmology at the University of Oxford.

Dr Gerard Boink, M.D., Ph.D.
Scientific Advisor

Gerard is a cardiologist at the Amsterdam UMC Heart Centre and holds an MSc in Pharmaceutical Sciences from the University of Amsterdam, in addition to MD and PhD degrees.

Professor Anders Kvanta, Ph.D.
Scientific Advisor

Anders is a professor in Ophthalmology at the Karolinska Institute and Senior Consultant in Vitreoretinal Surgery at St. Erik Eye Hospital.

Get in touch

Embark on a transformative journey with Alder Therapeutics and join us in our mission to cure the incurable.

Thank you! We get in contact with you as soon as possible!
Oops!
Something went wrong while submitting the form. Please try again!